Charles S. Berkman net worth and biography

Charles Berkman Biography and Net Worth

Insider of OmniAb

Charles Berkman, JD has served OmniAb’s Chief Legal Officer since March of 2022. Previously, Mr. Berkman served as Senior Vice President, General Counsel and Secretary at Ligand Pharmaceuticals from 2018 to 2022 and prior to that as Ligand’s Vice President, General Counsel and Secretary from 2007 to 2018. Mr. Berkman joined Ligand in November 2001 as Associate General Counsel and Chief Patent Counsel. Prior to that, Mr. Berkman was an attorney at the international law firm of Baker & McKenzie and an attorney at the law firm of Lyon & Lyon, where he specialized in intellectual property law. Mr. Berkman earned a BS in Chemistry from the University of Texas and a JD from the University of Texas School of Law.

What is Charles S. Berkman's net worth?: The estimated net worth of Charles S. Berkman is at least $715.53 thousand as of April 7th, 2025. Berkman owns 363,212 shares of OmniAb stock worth more than $715,528 as of December 5th. This net worth approximation does not reflect any other assets that Berkman may own. Additionally, Berkman receives a salary of $734,330.00 as Insider at OmniAb. Learn More about Charles S. Berkman's net worth.
How old is Charles S. Berkman?: Berkman is currently 55 years old. There are 3 older executives and no younger executives at OmniAb. The oldest executive at OmniAb is Dr. Douglas S. Krafte Ph.D., Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head, who is 66 years old. Learn More on Charles S. Berkman's age.
What is Charles S. Berkman's salary?: As the Insider of OmniAb, Inc., Berkman earns $734,330.00 per year. The highest earning executive at OmniAb is Mr. Matthew W. Foehr, President, CEO & Director, who commands a salary of $967,720.00 per year. Learn More on Charles S. Berkman's salary.
How do I contact Charles S. Berkman?: The corporate mailing address for Berkman and other OmniAb executives is 65 EAST 55TH STREET 18TH FLOOR, NEW YORK NY, 10022. OmniAb can also be reached via phone at 510-250-7800 and via email at [email protected]. Learn More on Charles S. Berkman's contact information.
Has Charles S. Berkman been buying or selling shares of OmniAb?: Charles S. Berkman has not been actively trading shares of OmniAb within the last three months. Most recently, Charles S. Berkman sold 7,206 shares of the business's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $2.00, for a transaction totalling $14,412.00. Following the completion of the sale, the insider now directly owns 363,212 shares of the company's stock, valued at $726,424. Learn More on Charles S. Berkman's trading history.
Who are OmniAb's active insiders?: OmniAb's insider roster includes Charles Berkman (Insider), Matthew Foehr (President and CEO), Kurt Gustafson (CFO), John Higgins (Director), and Steven Love (Director). Learn More on OmniAb's active insiders.
Are insiders buying or selling shares of OmniAb?: In the last year, OmniAb insiders bought shares 5 times. They purchased a total of 293,011 shares worth more than $533,319.37. In the last year, insiders at the sold shares 9 times. They sold a total of 150,811 shares worth more than $458,129.12. The most recent insider tranaction occured on November, 7th when Director John L Higgins bought 41,038 shares worth more than $56,632.44. Insiders at OmniAb own 8.6% of the company. Learn More about insider trades at OmniAb.
Information on this page was last updated on 11/7/2025.

Charles S. Berkman Insider Trading History at OmniAb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/7/2025	Sell	7,206	$2.00	$14,412.00	363,212
2/18/2025	Sell	8,215	$3.68	$30,231.20	364,131
1/21/2025	Sell	25,489	$3.24	$82,584.36	343,190

Charles S. Berkman Buying and Selling Activity at OmniAb

OmniAb Company Overview

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Today's Range

Now: $1.97

$1.86

$1.98

50 Day Range

MA: $1.64

$1.38

$1.97

2 Week Range

Now: $1.97

$1.22

$4.17

Volume

454,821 shs

Average Volume

503,386 shs

Market Capitalization

$283.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.13

Charles Berkman Biography and Net Worth

What is Charles S. Berkman's net worth?

How old is Charles S. Berkman?

What is Charles S. Berkman's salary?

How do I contact Charles S. Berkman?

Has Charles S. Berkman been buying or selling shares of OmniAb?

Who are OmniAb's active insiders?

Are insiders buying or selling shares of OmniAb?